Iressa Advisory Committee Will Not Vote On Oncologic’s Status – AstraZeneca

FDA will not make a regulatory decision on Iressa until survival study data have been fully analyzed, AstraZeneca says; the company expects to complete its data analysis by July. AstraZeneca will present “top-line” data from the ISEL survival study at the March 4 Oncologic Drugs Advisory Committee meeting.